Our research framework
FOXP1 Medical Research Foundation focuses on five interconnected investment areas. Together, these pillars form a roadmap that takes us from scientific understanding to real therapies in the hands of patients.
1
De-risking research
Shows that FOXP1 can be treated and that interventions in adolescence and adulthood can still make a meaningful impact.
This work is critical because it helps reduce the perceived risk for biotech and pharmaceutical companies considering investment in FOXP1 therapies.
2
Clinical research
Helps doctors and scientists better understand how a genetic condition affects people over time.
For example, natural history studies follow patients to learn how symptoms start, change, and progress. Researchers also create or adapt tools—like rating scales—to measure whether treatments are making a real difference in daily life. This kind of research is essential for improving care today and for paving the way toward safe, effective, FDA-approved therapies in the future.
3
Toolkit development
Focuses on creating scientific resources that can be shared across many different research efforts.
Examples include FOXP1 animal models that are freely available to researchers and biotech companies, and iPSC lines with FOXP1 mutations that can be used to build cellular models. These models include organoids—miniature, lab-grown models of organs such as the brain—as well as other in vitro systems used to study disease mechanisms and test potential therapies. By making these tools widely accessible, the Foundation helps remove barriers to entry, speeds up research, and lowers the cost of developing new treatments.
4
Foundational infrastructure
Aims to develop resources that establish the groundwork for drug development and approval.
These resources include educational tools for community and industry, prevalence estimates, ICD-10 code, and materials for FDA meetings. These assets will set us up for success in gaining community support, industry partners, and regulatory approval.
5
Treatment research
Centers the development and testing of real therapeutic options for FOXP1 syndrome.
Our work includes exploring multiple approaches and moving the most promising candidates forward into clinical trials and, ultimately, FDA approval. We will build on lessons learned from successful treatments for related neurodevelopmental conditions, while focusing on strategies most likely to benefit patients quickly. The FMRF is committed to engaging world-leading researchers, staying at the forefront of science, and prioritizing practical, rapidly translatable treatments over speculative or purely academic projects.